KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Capital Expenditures data on record, last reported at $522000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 569.23% year-over-year to $522000.0; the TTM value through Dec 2025 reached $562000.0, up 620.51%, while the annual FY2025 figure was $562000.0, 620.51% up from the prior year.
  • Capital Expenditures reached $522000.0 in Q4 2025 per AQST's latest filing, up from -$43000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $826000.0 in Q2 2023 and bottomed at -$979000.0 in Q4 2023.
  • Average Capital Expenditures over 5 years is $128850.0, with a median of $93000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: plummeted 3865.38% in 2023, then skyrocketed 1350.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $533000.0 in 2021, then tumbled by 95.12% to $26000.0 in 2022, then tumbled by 3865.38% to -$979000.0 in 2023, then soared by 107.97% to $78000.0 in 2024, then soared by 569.23% to $522000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $522000.0 in Q4 2025, -$43000.0 in Q3 2025, and -$52000.0 in Q2 2025.